Thirty-two evaluable patients with advanced epithelial ovarian cancer were treated with aminothiadiazole at a dosage of 125 mg/m2 weekly. Two patients had partial responses, 12 had stable disease, 16 had increasing disease, and two were inevaluable for response. Aminothiadiazole used in this dosage and schedule has minimal activity in ovarian carcinoma patients previously treated.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00000421-198608000-00012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of asymmetric nasal high-flow cannula on carbon dioxide in hypercapnic patients: A randomised crossover physiological pilot study.
Pulmonology
December 2025
Alma Mater Studiorum, Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
Nasal high flow (NHF) therapy is an established form of non invasive respiratory support used in acute and chronic care. Recently, a new high flow nasal cannula with asymmetric prongs was approved for clinical use. The clinical benefits of the new cannula have not yet been defined and no evidence are available on the use of asymmetric NHF support in patient with Chronic Obstructive Pulmonary Disease (COPD).
View Article and Find Full Text PDFUsing Large Language Models to Detect and Understand Drug Discontinuation Events in Web-Based Forums: Development and Validation Study.
J Med Internet Res
January 2025
Department of Industrial and Systems Engineering, The University of Florida, GAINESVILLE, FL, United States.
Background: The implementation of large language models (LLMs), such as BART (Bidirectional and Auto-Regressive Transformers) and GPT-4, has revolutionized the extraction of insights from unstructured text. These advancements have expanded into health care, allowing analysis of social media for public health insights. However, the detection of drug discontinuation events (DDEs) remains underexplored.
View Article and Find Full Text PDFMyocardial extracellular volume fraction estimations using late enhancement CT in patients with atrial fibrillation: a comparative study with cardiac MR.
Int J Cardiovasc Imaging
January 2025
Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, 2-174, Edobashi, Tsu, Mie, 514-8507, Japan.
Myocardial extracellular volume fraction (ECV) measured via MRI serves as a quantitative indicator of myocardial fibrosis. However, accurate measurement of ECV using MRI in the presence of AF is challenging. Meanwhile, CT could be a promising alternative tool for measuring ECV regardless of sinus rhythm or AF.
View Article and Find Full Text PDFReal-world application of CCTA with CT-FFR for coronary assessment pre-TAVI: the CT2TAVI study.
Int J Cardiovasc Imaging
January 2025
Cardiology, Endeavor NorthShore Cardiovascular Institute, Evanston, IL, USA.
This study aims to evaluate the implementation of concomitant CAD assessment on pre-TAVI (transcatheter aortic valve implantation) planning CTA (CT angiography) aided by CT-FFR (CT-fractional flow reserve) [The CT2TAVI protocol] and investigates the incremental value of CT-FFR to coronary CT angiography (CCTA) alone in the evaluation of patients undergoing CT2TAVI. This is a prospective observational real-world cohort study at an academic health system on consecutive patients who underwent CTA for TAVI planning from 1/2021 to 6/2022. This represented a transition period in our health system, from not formally reporting CAD on pre-TAVI planning CTA (Group A) to routinely reporting CAD on pre-TAVI CTA (Group B; CT2TAVI protocol).
View Article and Find Full Text PDFProgress and prospects in antisense oligonucleotide-mediated exon skipping therapies for Duchenne muscular dystrophy.
J Muscle Res Cell Motil
January 2025
Institute of Developmental and Regenerative Medicine, University of Oxford, IMS-Tetsuya Nakamura Building, Old Road Campus, Roosevelt Dr, Headington, Oxford, OX3 7TY, UK.
Recent years have seen enormous progress in the field of advanced therapeutics for the progressive muscle wasting disease Duchenne muscular dystrophy (DMD). In particular, four antisense oligonucleotide (ASO) therapies targeting various DMD-causing mutations have achieved FDA approval, marking major milestones in the treatment of this disease. These compounds are designed to induce alternative splicing events that restore the translation reading frame of the dystrophin gene, leading to the generation of internally-deleted, but mostly functional, pseudodystrophin proteins with the potential to compensate for the genetic loss of dystrophin.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!